| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | beclometasone dipropionate anhydrous/formoterol fumarate dihydrate (Fostair NEXThaler®) |
| Formulation | 100 mcg/6 mcg inhalation powder |
| Reference number | 2931 |
| Indication | Symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. Fostair NEXThaler is indicated in adults |
| Company | Chiesi Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 04/11/2015 |